Ptc Therapeutics, Inc. (PTCT) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001070081

P/B -37.99

P/E 7.87

P/S 3.33

Market Cap 5.92 Bn

ROIC (Qtr) -241.73

Div Yield % 0.00

Rev 1y % (Qtr) 7.23

Total Debt (Qtr) 410.13 Mn

Debt/Equity (Qtr) -2.63

About

Strong operating cash flow of 715.47M provides robust 1.74x coverage of total debt 410.13M, indicating excellent debt servicing capability and financial flexibility.
Healthy cash reserves of 672.62M provide 2.24x coverage of short-term debt 300.81M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 2.16B provides 5.28x coverage of total debt 410.13M, indicating robust asset backing and low credit risk.
Strong operating cash flow of 715.47M provides 2.14x coverage of SG&A expenses 334.95M, showing efficient operational cost management.
Tangible assets of 2.16B provide exceptional 1280.24x coverage of deferred revenue 1.69M, showing strong service capability backing.

Operating cash flow of 715.47M barely covers its investment activities of (628.28M), with a coverage ratio of -1.14, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of (628.28M) provide weak support for R&D spending of 446.89M, which is -1.41x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Cash reserves of 672.62M provide limited coverage of acquisition spending of (258.96M), which is -2.60x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
High receivables of 203.07M relative to inventory of 52.69M (3.85 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
Free cash flow of 855.28M provides weak coverage of capital expenditures of (139.82M), with a -6.12 ratio suggesting additional external financing needs for growth initiatives.

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Metric	Value	Industry
EV to Assets	2.00	12.31
EV to Cash from Ops.	7.39	23.25
EV to Debt	12.89	738.44
EV to EBIT	6.01	-9.16
EV to EBITDA	6.57	6.95
EV to Free Cash Flow [EV/FCF]	6.18	21.90
EV to Market Cap	0.89	65.67
EV to Revenue	2.97	227.32
Price to Book Value [P/B]	-37.99	22.34
Price to Earnings [P/E]	7.87	-11.77

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	6.37	841.00

Metric	Value	Industry
Capex Growth (1y) %	607.75	-27.13
Cash and Equivalents Growth (1y) %	27.87	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	428.00	-46.93
EBITDA Growth (1y) %	2,973.06	-1.68
EBIT Growth (1y) %	444.39	-56.45
EBT Growth (1y) %	274.16	-12.70
EPS Growth (1y) %	261.78	-28.31
FCF Growth (1y) %	640.58	-31.90
Gross Profit Growth (1y) %	107.46	226.84

Metric	Value	Industry
Asset Utilization Ratio	0.67	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	0.78	3.85
Current Ratio	2.32	7.27
Debt to Equity Ratio	-2.63	0.40
Interest Cover Ratio	6.37	841.00
Times Interest Earned	6.37	841.00

Metric	Value	Industry
EBITDA Margin %	51.60	-18,234.31
EBIT Margin %	49.41	-18,580.80
EBT Margin %	41.65	-19,488.74
Gross Margin %	96.80	-7.59
Net Profit Margin %	42.30	-19,439.22